hackettg

As part of our Funding & Reimbursement Shorts series, Community Pharmacy England’s in-house Drug Tariff funding and regulatory experts have created a new video on out-of-pocket (OOP) expenses. In this video, we explain how pharmacy teams can claim out-of-pocket expenses incurred when obtaining eligible drugs or appliances for dispensing against NHS prescriptions. We also cover [...]

The post Funding & Reimbursement Shorts: Out-of-pocket (OOP) expenses appeared first on Community Pharmacy England.

The Drug Tariff Preface published monthly, lists additions, deletions and other changes to products listed in the Drug Tariff. Below is a summary of the changes coming into effect from 1 February 2026. Key g Special container – This product is a special container and should be dispensed in its complete original pack size. n Item requiring reconstitution [...]

The post Drug Tariff Watch – February 2026 appeared first on Community Pharmacy England.

MHRA Class 4 Medicines Defect Notification: Arixtra solution for injection pre-filled syringes (Viatris Products Ltd) Drug alert number: EL(26)A/04 Date issued: 28 January 2026 Viatris has received reports of brown discolouration and blockage in the needle of pre-filled syringes of Arixtra. This quality defect is related to oxidation of the syringe needle. DMRC reference number:DMRC-38220370 Marketing [...]

The post MHRA Class 4 Medicines Defect Notification: Arixtra solution for injection pre-filled syringes (Viatris Products Ltd) appeared first on Community Pharmacy England.

MHRA Class 3 Medicines Recall: Prednisolone 5mg Soluble Tablets (Activase Pharmaceuticals Limited) Drug Alert Number: EL(25)A/54 Date issued: 15 December 2025 Activase Pharmaceuticals Limited is recalling two batches of Prednisolone 5mg Soluble Tablets as a precautionary measure due to a limited number of reports of blister pockets becoming swollen over time. DMRC reference number: DMRC – 37820855 [...]

The post MHRA Class 3 Medicines Recall: Prednisolone 5mg Soluble Tablets (Activase Pharmaceuticals Limited) appeared first on Community Pharmacy England.

From 1 December 2025, the use of the ‘FS’ prescriber endorsement has been extended to treatments used in the management of tuberculosis (TB) and latent TB infections, including the effects of TB and the adverse effects from TB treatment. Pharmacy teams should ensure that no prescription charge is levied for any items endorsed ‘FS’ by [...]

The post Use of ‘FS’ endorsement extended to Tuberculosis (TB) treatments appeared first on Community Pharmacy England.